Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TF0023 in hospitalized adults with COVID-19
2021-000748-24Phase 2Terminated
- Sponsor
- Techfields Inc.
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing TF0023 with Placebo (2 arms). Primary endpoint: Percentage of patients able to maintain peripheral capillary oxygen saturation above 93% without oxygen support at Day 15. Started Jul 2022; status: terminated.
02
Drugs
2-(diethylamino)ethyl 2-acetyloxybenzoate hydrochloride
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-000748-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000748-24.